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Abstract
Purpose Late-stage OTSCC is associated with poor overall survival (OS). Non-curative treatment approach aims to improve 
quality of life and prolong survival of patients deemed incurable. The purpose of this study was to investigate the used non-
curative treatment modalities for OTSSC and patient survival.
Methods All patients diagnosed with OTSCC and treated with non-curative intent at the HUS Helsinki University Hospital 
(Helsinki, Finland) during the 12-year period of 2005–2016 were included. Survival analysis after the non-curative treatment 
decision was conducted using the Kaplan–Meier method in this population-based study.
Results Eighty-two patients were identified. A non-curative treatment decision was made at presentation without any pre-
vious treatment in 26 patients (7% of all patients diagnosed with OTSCC during the study period). Palliative radiotherapy 
was administered to 24% of all patients. The average survival time after the non-curative treatment decision was 3.7 months 
(median 2 and range 0–26).
Conclusions Due to the short mean survival time after decision for treatment with non-curative intent, and the notable 
symptom burden in this patient population, a prompt initiation of all non-curative measures is warranted.
Keywords Head and neck cancer · Tongue cancer · Palliative care · Palliation · Surgery · Chemotherapy · End of life · 
Quality of life · Death
Introduction
Non-curative treatment constitutes an interdisciplinary treat-
ment effort for patients whose disease is unresponsive to 
approaches with curative intent and involves life-prolonging 
treatment and palliative care. Some patients, either at pres-
entation, during the course of therapy or later during fol-
low-up, will experience advanced and progressive disease, 
which may require a shift in the objective of medical care. 
Although life-prolonging treatment, also called disease-
modifying or disease-stabilising treatment, can provide pro-
longed disease control with the current armamentarium of 
treatment modalities, side effects often reduce the patient’s 
quality of life. Recently, more research has also been aimed 
at further developing palliative care. Development has also 
been made in symptom management of advanced disease, 
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as the impact of various aspects of palliative care is better 
recognized [1–4].
End-stage head and neck cancer (HNC) typically has pro-
found effects and symptom burden on the patient’s airway, 
upper gastrointestinal tract, major senses, physical appear-
ance, and self-esteem as well as social life and normal daily 
functions. Palliative care modalities, which also include 
radiotherapy and surgical interventions, play a critical role 
in improving quality of life of the patient by alleviating 
tumour-related symptoms. Still, the functional deficits and 
symptomology caused by HNCs, due to the distinctive pro-
file of the cancer itself in combination with the organs and 
tissues affected, remain a challenge even for experienced 
multidisciplinary centres [4, 5].
While early stage oral tongue squamous-cell carcinoma 
(OTSCC) has a favourable prognosis with high cure rates, 
late-stage OTSCC is associated with poor overall survival 
(OS). Despite improvements in the treatment outcomes of 
OTSCC in Finland, significant morbidity and mortality rates 
still affect this patient population, and a considerable propor-
tion of patients will succumb to their disease. Furthermore, 
several patients each year present with end-stage disease and 
are unsuitable for curatively intended therapy [6]. There is 
a dearth of data on non-curative treatment related to oral 
cancer. Moreover, no previous study to our knowledge has 
specifically focused on life-prolonging treatment or pallia-
tive care of end-stage OTSCC patients. Such studies would 
provide insight on various clinical aspects of palliative care 
for OTSCC and allow improvement of treatment protocols. 
Therefore, the purpose of this study was to investigate the 
implemented non-curative, i.e., life-prolonging treatment 
and palliative care, modalities of OTSCC, and patient sur-
vival at the HUS Helsinki University Hospital during a 
12-year period from 2005 to 2016.
Patients and methods
All patients diagnosed with OTSCC and treated with non-
curative intent at the HUS Helsinki University Hospital 
(Helsinki, Finland) during the 12-year period between Janu-
ary 1st, 2005 and December 31st, 2016 were included. Sub-
jects were identified from hospital registries with the ICD-10 
diagnosis codes (C02.0, C02.1, C02.2, C02.3, and C02.9). 
Only histologically verified cases of epithelial cancer located 
in the mobile tongue were included.
Clinicopathological data were obtained from hospital 
records for the following parameters: age, sex, smoking and 
drinking habits, previous cancers, dental status, date of path-
ological diagnosis, tumour histopathology, tumour location, 
TNM class, treatment of the primary tumour, reconstruc-
tion, neck dissection, radio- and chemotherapy, use of tra-
cheostomy or percutaneous endoscopic gastrostomy, date of 
surgery, date of start and end of radiotherapy, disease recur-
rence (location and date of diagnosis), date of non-curative 
treatment decision, date of the beginning of non-curative 
treatment, date and status at last follow-up at the palliative 
unit, and date and place of death.
Non-curative treatment comprises life-prolonging treat-
ment and palliative care. While life-prolonging treatment 
was administered with the intention to improve patient sur-
vival with means of chemo-, radio, or chemoradiotherapy, 
palliative care was considered to have been started after the 
termination of curatively intended or life-prolonging treat-
ment. We use the term “palliative treatment” when referring 
to surgery or radiotherapy given with non-curative intent 
with the aim to alleviate symptoms, not to prolong life. 
Patient survival analysis after decision of treatment with 
non-curative intent was conducted using the Kaplan–Meier 
method with R (version 3.5.1). Clinical data on a subgroup 
of the patients diagnosed and treated during 2005–2009 have 
been published previously [6]. Research permission for the 
study design was granted by the National Institute for Health 
and Welfare (Dnro THL/264/5.05.00/2015).
Results
Three hundred and fifty patients with primary OTSCC were 
identified (42% female) during the 12-year study period. A 
total of 82 (23%) out of the 350 patients received treatment 
with non-curative intent (40% female; mean age 66.1 years; 
median 65, range 28–94.4) at some phase of their man-
agement. A non-curative treatment decision was made at 
presentation without any previous treatment in 26 patients 
(7% of all patients diagnosed with OTSCC during the study 
period). Palliative care was the primary goal of treatment 
without any previous treatment for 20 patients (24% of the 
82 patients who received treatment with non-curative intent 
and 6% of all 350 patients diagnosed with OTSCC during 
the study period). Palliative care was administered for 14 
patients because of failure of curative treatment or persis-
tent disease. Clinical characteristics of the study group are 
presented in Table 1 and the flowchart showing various sub-
groups in Fig. 1.
Forty-six (56%) patients reported tobacco use and twenty-
nine (35%) heavy alcohol consumption (defined in our study 
as more than 16 alcohol units for women and more than 
24 alcohol units for men a week according to the Finnish 
national guidelines on classifying alcohol consumption) at 
the time of diagnosis. The majority of patients (n = 45, 54%) 
were found to be in need of dental treatment.
Of the patients receiving either only palliative care 
(n = 20, 24%) or life-prolonging treatment (n = 6) during the 
primary phase of treatment without any previous treatment, 
20 (77%) had Stage IV disease, and of these, three were 
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diagnosed with distant metastatic disease at presentation and 
three had already been diagnosed with another end-stage 
cancer. In five (6%) patients, all diagnosed with Stage IV 
disease, a palliative care plan was adopted after failure of 
curatively intended treatment. After surgical treatment, two 
of these patients received palliative radiotherapy and three 
received only symptomatic treatment. Disease control after 
primary phase treatment with curative intent, defined as no 
disease persistence or disease recurrence within 3 months 
after completion of treatment with curative intent, could not 
be accomplished in nine patients (2.6% of all the patients 
diagnosed and treated for OTSCC in our center during the 
study period), who were subsequently treated either with 
life-prolonging treatment (three patients) or only with pal-
liative care (Fig. 1).
Forty-two patients (51% of patients treated with non-
curative intent) received non-curative treatment after dis-
ease recurrence. Twenty-one (26%) patients experienced 
locoregional disease recurrence and distant metastases were 
diagnosed in 27 (33%) patients. It should be noted that, in 
one patient, the nature of a hypopharyngeal tumour could 
not be confirmed histologically as a recurrence and could 
have been a second primary tumour.
The average treatment delay after the non-curative treat-
ment decision for patients receiving life-prolonging treat-
ment was 19 days (median 19 and range 0–56). For patients 
treated with palliative surgery or radiotherapy, the average 
treatment delay after treatment decision was 25 days (median 
18, range 5–167). Correspondingly, the mean interval time 
from diagnosis of primary or recurrent disease to treatment 
for patients administered life-prolonging treatment was 
50 days (median 31 and range 0–266) and the mean interval 
time between start of life-prolonging treatment and shift to 
palliative care was 165 days (median 142, range 15–452).
Twenty (24%) patients received life-prolonging treatment. 
Chemotherapy, with or without combination radiotherapy, 
was used for 13 (16%) patients. Six patients received cetux-
imab in combination with 5-fluoroacil (5-FU) and cispl-
atin and four patients received paclitaxel with or without 
concomitant carboplatin. Boron neutron capture therapy 
(BNCT) was administered to six patients (7%). Invasive sur-
gical procedures were undertaken in a non-curative setting 
in 6% (n = 5) of patients. As palliative treatment, one patient 
underwent salvage surgery, and two total glossectomies and 
one debulking neck surgery were performed. Palliative radi-
otherapy was administered to 20 (24%) patients in the form 
of conventionally fractionated radiotherapy with a total dose 
ranging from 6 to 30 Gy in fractions of 2 to 3 Gy. Almost 
half of all patients (48%; n = 39), and 31% (n = 8) of patients 
treated without any curative intent, received only sympto-
matic treatment without any adjuvant treatment. Percutane-
ous endoscopic gastrostomy (PEG) feeding was pursued in 
53 (65%) patients; 23 of whom (28% of all patients) also 
underwent tracheostomy (Table 2).
In the whole patient series, only one patient (female, age 
94) refused the offered curatively intended treatment and 
received subsequently only symptomatic treatment. Among 
the patients treated with non-curative intent, one patient had 
declined the recommended neck dissection and one patient 
had declined radiotherapy as part of the initial curative treat-
ment. In two cases, the ongoing palliative radiotherapy had 
to be interrupted due to lack of treatment compliance.
The average survival time after the non-curative treat-
ment decision was 3.7 months (median 2 and range 0–26). 
For patients administered life-prolonging treatment and 
for patients who received only palliative care without 
previous life-prolonging treatment, the average survival 
times after decision of treatment with non-curative intent 
were 7.9 (median 7, range 2–26) and 2.5 months (median 
1.5, range 0–24), respectively. For patients treated with 
palliative surgery and/or radiotherapy and for patients 
Table 1  Clinical characteristics of 82 OTSCC patients treated with 
non-curative intent in Helsinki during 2005–2016





 < 39 3 (4)
 40–59 18 (22)
 60–79 48 (59)
 > 79 13 (16)






 No data 1 (4)
Tobacco use, cigarettes per day
 Non-smoking 19 (23)
 < 10 2 (2)
 ≥ 10 45 (55)
 No data 16 (20)
Alcohol use, drinks per week





 Health care centre 10 (12)
 Nursing home 3 (4)
 Unknown 10 (12)
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receiving only symptomatic treatment (without previous 
life-prolonging treatment), the average survival times after 
non-curative treatment decision were 3.7 months (median 
2, range 1–24) and 1.7 months (median 1, range 0–11), 
respectively. Seven (9%) patients survived over a year after 
the decision of non-curative treatment intent; five of these 
patients received life-prolonging treatment. OS after deci-
sion of treatment with non-curative intent is presented in 
Fig. 2. The average survival time for patients treated with 
non-curative intent after diagnosis of disease recurrence 
was 6.6 months (median 3 and range 0–30). Correspond-
ingly, the average elapsed time after last follow-up assess-
ment at the Departments of Otorhinolaryngology-Head 
and Neck Surgery or Oral and Maxillofacial Surgery to 
the date of death was 1.5 months (median 27 days, range 
0–17 months). In the present patient series, six patients 
(9%) died of other causes (other cancer in five cases).
Hospital ward was the most common place of death (30 
patients, 37%). Of the patients dying at a hospital ward, 
37% (n = 11) died at a university hospital. Ten (12%) 
patients died on a primary health care center ward, 16 
(20%) in a hospice, three (4%) in a nursing home, 13 (16%) 
at home, and 12 (10%) at an unknown location.
Fig. 1  Consort flow diagram: 
OTSCC patient selection
Table 2  Treatment with non-curative intent given to 82 patients diag-
nosed with OTSCC in Helsinki during 2005–2016
Treatment n (%)
Palliative surgery 3 (4)
Palliative surgery and radiotherapy 2 (2)
Palliative radiotherapy 18 (22)
Life-prolonging radiotherapy 7 (9)
Life-prolonging chemotherapy 7 (9)
Life-prolonging chemoradiotherapy 6 (7)
Only symptomatic treatment 39 (48)
82 (100)
PEG feeding 30 (37)
Tracheostomy 2 (2)
PEG feeding and tracheostomy 23 (28)
No PEG or tracheostomy 27 (33)
82 (100)
2043European Archives of Oto-Rhino-Laryngology (2019) 276:2039–2045 
1 3
Discussion
HNCs comprise a heterogeneous group of malignancies 
with site-specific characteristics for individual tumours. 
Oral cancer is the most common site with OTSCC being 
its most frequently occurring cancer type and with a stead-
ily rising incidence in several countries [7, 8]. While the 
early stage OTSCC has a favourable prognosis with high 
cure rates, late-stage OTSCC is associated with poor OS and 
higher disease recurrence rates [6]. Furthermore, its treat-
ment often results in significant morbidity. In addition to 
the symptomology associated with the disease itself, these 
patients often experience major comorbidities and complex 
psychosocial concerns. Life-prolonging treatment and pal-
liative care are advocated for patients deemed incurable and 
for those who are non-responsive to curative treatment. The 
main aim remains to improve quality of life in this patient 
population, but, sometimes, also prolonged survival time 
will be achieved [1, 4]. This study was conducted to inves-
tigate the treatment concepts and patient survival for 82 
patients treated for OTSCC with non-curative intent at the 
Helsinki University Hospital during 2005–2016, and, there-
fore, adds epidemiological content to the current scarce lit-
erature on the palliative care of OTSCC patients.
During the 12-year study period, a total of 1462 new 
tongue cancers were diagnosed in Finland according to the 
Finnish Cancer Registry (https ://www.cance rregi stry.fi). 
Therefore, the present series constitutes one quarter (24%) of 
this nation-wide cohort and, thus, forms a population-based 
study in Southern Finland. In our cohort, non-curative treat-
ment intent was recommended for 7% of patients presenting 
with newly diagnosed primary OTSCC, most of them having 
Stage IV disease (83%). These findings are in accordance 
with the previous studies conducted in Finland [5, 9] and 
elsewhere [10]. For instance, Heinonen et al. [5] reported 
that 9% of newly diagnosed primary HNC patients at the 
HUS Helsinki University Hospital are referred for palliative 
care at presentation. In our previous nationwide study on 
OTSCC [6], we could additionally note that 21 (32%) out 
of 65 patients presenting with Stage IV disease at the first 
presentation were treated with non-curative intent with or 
without life-prolonging treatment.
A significant proportion of patients experiencing dis-
ease recurrence will eventually be recommended treatment 
with non-curative intent. Twenty-seven patients (23% of 
all patients) diagnosed with OTSCC at the Helsinki Uni-
versity Hospital during 2005–2009 had disease recurrence 
during the 5-year follow-up; 21 (78%) patients of this sub-
group were eventually treated with non-curative intent [6]. 
This underlines the importance of an established protocol, 
resources, and infrastructure for palliative care, which may 
often have a prominent role in the treatment of patients with 
disease recurrence. Therefore, palliative care needs should 
be assessed already during the initial treatment upon the 
diagnosis of disease recurrence, as disease recurrence is 
associated with substantial symptom burden and low sur-
vival [4, 6]. In this study, while 21 (26%) patients received 
palliative care after curatively intended treatment of the dis-
ease recurrence (eight patients in this group also received 
life-prolonging treatment), in another group of 21 patients, 
the disease recurrence was determined incurable and con-
sequently, a palliative care approach was implemented for 
most patients (three patients in this group had also previ-
ously received life-prolonging treatment).
According to studies, palliative radiotherapy is commonly 
advocated for patients with incurable malignant disease of 
the head and neck [11, 12]. In the current study, 22% of 
patients received radiotherapy as a palliative monotherapy 
and 7% with concomitant chemotherapy. A similar finding 
has been reported in other HNC patient series evaluated in 
Finland [5]. The goal of treatment in these patients is to alle-
viate the cancer-related devastating symptoms to improve 
quality of life while minimizing potential side effects, such 
as mucositis [12]. Therefore, radiotherapy should be given 
in the shortest possible time and its benefits should be judi-
ciously pondered against the possible side effects. Moreover, 
in certain cases, radiotherapy can be hindered by radiore-
sistance of the tumour, resulting in limited therapeutic gain 
[13]. Untreated HNC appears to be chemosensitive [14–16]. 
However, the efficacy of chemotherapy in recurrent disease 
is limited due to development of drug resistance [17]. A 
combination of cisplatin and 5-fluorouracil is the standard 
first-line treatment regimen to which new combinations are 
compared [18]. Studies have reported an improved survival 
for oral cancer patients with unresectable tumours treated 
with chemotherapy [19]. Chemotherapy was used only in 
0 5 10 15 20 25
Survival after decision of treatment 
with non-curative intent



















No life-prolonging treatment, n=62
Fig. 2  Overall survival after non-curative treatment decision with 
grouping according to treatment for 82 patients diagnosed with 
OTSCC at the Helsinki University Hospital during 2005–2016
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16% of patients in this cohort and cetuximab in combination 
with cisplatin and 5-fluorouracil was mostly administered. 
The median OS for patients treated with chemotherapy was 
3 months after start of treatment. However, differences in OS 
among different treatment regimens could not be statistically 
compared due to the low number of patients in this series. 
Still, the short OS warrants palliative care to be initiated 
alongside chemotherapy.
Palliative surgery is used only in selective cases [20]. In 
our study, only 6% of patients underwent palliative surgery. 
This low figure could be explained by the sequels and com-
plications associated with surgery of large tumours and also 
by the infeasibility of palliative surgery in various cases with 
short expectancy for survival. Almost half of the patients 
received only symptomatic treatment, possibly due to associ-
ated comorbidities, compromised overall physical condition, 
previous radiotherapy, and, in two cases, due to lack of co-
operation. Treatment refusal in this patient group was rare. 
However, Schwam et al. [21] reported a refusal rate of 4% 
for postoperative radiotherapy after curative surgery. Simi-
larly, Stavas et al. [22] reported a 3% rejection of palliative 
radiotherapy in lung cancer patients. To our knowledge, no 
studies on the prevalence of refusal of treatment with non-
curative intent for HNCs have been conducted yet.
The use of PEG in patients undergoing radiotherapy can 
be beneficial for the patients, but carries the risk of com-
plications. Side effects such as pain and PEG leakage, but 
also rare major complications, as colonic perforation due to 
PEG malposition and peritonitis, have been described [23, 
24]. A high rate of unnecessary prophylactic PEG placement 
in patients with HNCs has also been reported [25]. PEG 
use was also not associated with improved survival, but it 
did reduce the need for hospitalization [26]. In the current 
cohort, PEG feeding was used in 65% of the patients, which 
is comparable to figures reported for oropharyngeal cancer 
patients [26]. Heinonen et al. [5] reported a 45% use of PEG 
in HNC patients. OTSCC is associated with functional dis-
abilities, which can restrict food intake and affect the upper 
airway, plausibly justifying the relatively high percentage of 
PEG use in the present patient population.
The reported survival times for HNC patients treated with 
non-curative treatment remain short in general. Kamisetty 
et al. [27] reported a median survival of 4.3 months (range 
2.1–8) for oral cancer patients, whereas Ledeboer et al. 
[10] reported a mean survival of 5.4 months and Heinonen 
et al. [5] reported a median survival of 3 months for HNC 
patients. These results are comparable to our findings with 
the median survival time for OTSCC patients after non-cura-
tive treatment decision being 2(<= two) months. In the pre-
sent patient cohort, only seven patients (9%) survived over 
a year after decision of non-curative treatment. One of these 
patients (female, age 94) refused the proposed curatively 
aimed treatment for Stage II disease and, thus, received only 
symptomatic treatment. Two other patients (male, age 69 and 
57) presenting with Stage IV disease received life-prolong-
ing treatment without any previous treatment. The other four 
patients (all male, average age 65) were eventually treated 
with non-curative intent after disease recurrence. Still, the 
median survival time after diagnosis of disease recurrence 
was 3 months. These low figures warrant a prompt initia-
tion of palliative care, as survival is relatively short and the 
complex symptoms associated with the disease can rapidly 
deteriorate the quality of life. The majority of patients died 
at the hospital and only 16% died at home. Recent studies 
have emphasized that the place of death influences not only 
the patient’s quality of life during the end-of-life period but 
also the mental well-being of the family members and car-
egivers [3, 27, 28]. Still, the majority of patients spend their 
final days at the hospital, which may be explained, at least 
partly, by the severity of the symptoms and, thus, by the 
warranted medical and technical expertise. In addition, the 
medical costs involved in home care may have a role.
Certain limitations in this retrospective study should be 
pointed out. One limitation is that no data were collected 
concerning comorbidities, which can substantially influence 
treatment decisions and OS. Another limitation was that we 
could not evaluate satisfaction for treatment and quality of 
life of the patients and caregivers. In addition, as mentioned 
previously, differences in outcome between treatment modal-
ities could not be assessed, due to the relatively small num-
ber of patients in the cohort. Future research is warranted to 
examine the impact of these differences on patient survival 
and quality of life.
We conclude that the survival time for OTSCC patients 
treated primarily with non-curative intent remains very 
short. Still, the median treatment delay in the present study 
was 18–19 days, which may be considered long for this 
patient population.
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